TNF Pharmaceuticals announces topline results from MYMD-1 study

TNF Pharmaceuticals (TNFA) announced that topline results from a Phase 2a study of its lead drug candidate MYMD-1 was presented at a international congress of global experts in sarcopenia and related disorders held December 6-8 in Washington, D.C. The presentation, ‘Isomyosamine for the Treatment of Sarcopenia in Elderly Population,’ describes the results of a double-blind, placebo-controlled study in patients aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Subjects in the trial who were given once daily oral doses of MYMD-1 showed significant decreases in several biomarkers attributed to chronic inflammation, including tumor necrosis factor-alpha, Interleukin-6 and soluble TNF-a receptor 1 at several timepoints throughout the 28 days of treatment. No serious adverse events were reported.